2,6-Dichloro-4-methylbenzaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-Dichloro-4-methylbenzaldehyde
• 化学式: C₈H₆Cl₂O
• mdl: MFCD09753749
• 分子量: 189.04
• InChiKey: AACXQAPPAREFQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] PYRAZOLE AMIDE DERIVATIVE<br/>[FR] DÉRIVÉ DE PYRAZOLE AMIDE
  申请人：TEIJIN PHARMA LTD

  公开号：WO2015129926A1

  公开（公告）日：2015-09-03

  The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

  本发明涉及一种新型化合物，具有抑制RORγ活性的功能。本发明还涉及包括该化合物的药物组合物，以及在治疗或预防自身免疫疾病、炎症性疾病、代谢性疾病或癌症疾病中使用该化合物的用途。
• FXR (NR1H4) MODULATING COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20170355693A1

  公开（公告）日：2017-12-14

  The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本公开涉及一般与结合NR1H4受体（FXR）并作为FXR激动剂的化合物有关。本公开进一步涉及利用这些化合物制备药物，用于通过这些化合物结合所述核受体治疗疾病和/或病况，以及用于合成这些化合物的过程。
• Pyrazole Amide Derivative
  申请人：AMGEN INC.

  公开号：US20150266824A1

  公开（公告）日：2015-09-24

  The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

  本发明涉及一种新型化合物，具有抑制RORγ活性的功能。本发明还涉及包含该化合物的药物组合物，以及使用该化合物治疗或预防自身免疫性疾病、炎症性疾病、代谢性疾病或癌症疾病的用途。
• AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：EP3730487A1

  公开（公告）日：2020-10-28

  The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本公开一般涉及与 NR1H4 受体 (FXR) 结合并作为 FXR 激动剂的化合物。本公开进一步涉及化合物在制备通过所述化合物结合所述核受体治疗疾病和/或病症的药物中的用途，以及所述化合物的合成工艺。
• FXR (NR1H4) modulating compounds
  申请人：Gilead Sciences, Inc.

  公开号：US10329286B2

  公开（公告）日：2019-06-25

  The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本公开一般涉及与 NR1H4 受体 (FXR) 结合并作为 FXR 激动剂的化合物。 本公开进一步涉及化合物在制备通过所述化合物结合所述核受体治疗疾病和/或病症的药物中的用途，以及所述化合物的合成工艺。